Autolus Therapeutics Reports Strong AUCATZYL Revenue Growth and Expands Pipeline
Event summary
- AUCATZYL generated $23.3 million in Q4 2025 revenue and $74.3 million for the full year, driven by U.S. sales.
- UK launch of AUCATZYL commenced in January 2026 following NICE evaluation.
- Autolus projects 2026 AUCATZYL net product revenue between $120 million and $135 million with a shift to positive gross margin.
- Real-world data from the ROCCA consortium confirms high clinical activity and favorable safety profile for AUCATZYL.
- Pivotal Phase 2 trials for obe-cel in lupus nephritis and pediatric ALL are enrolling, with initial data expected by year-end 2026.
The big picture
Autolus Therapeutics is solidifying its position in the CAR-T cell therapy market with strong revenue growth from AUCATZYL and strategic expansions into new indications. The company's focus on operational efficiencies and pipeline advancements aligns with broader industry trends toward cost-effective, scalable manufacturing solutions for advanced therapies.
What we're watching
- Revenue Growth
- Whether Autolus can sustain the projected $120 million to $135 million in AUCATZYL revenue for 2026.
- Clinical Pipeline
- The pace at which obe-cel advances through Phase 2 trials in lupus nephritis and pediatric ALL, with initial data expected by year-end 2026.
- Operational Efficiency
- How Autolus' manufacturing life cycle plan will impact cost reductions and gross margin improvements.